Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Moon rocket and weather are on NASA's side for the first astronaut launch in decades - 2Women take pride in Holy Week roles after a Spanish Catholic brotherhood's procession excluded them
- 3Pick Your #1 game to observe
- 4Robert Pattinson claims he's a pathological liar. What 'The Drama' star has said about his 'shtick'
- 5China resumes flights to North Korea after a six-year pause
- 12 times rockets and spacecraft crashed and burned in 2025
- How to see the Ursids, the final meteor shower of 2025
- Whale stranded in the Baltic Sea swims free again. It still faces a tough task
- These four astronauts could soon travel farther from Earth than anyone has gone before
- Euclid space telescope sees gorgeous cosmic cloud | Space photo of the day for Nov. 18, 2025
- Young Muslims in Germany feel left out of Mideast debate, experts say
- The most effective method to Pick the Right Material Organization: Fundamental Tips
- Extraordinary Shows to Long distance race on a Plane
- Louisiana seeks California doctor’s extradition, testing the limits of shield laws
